Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) appears undervalued with strong profitability, financial health, and growth potential, making it a candidate for value investors.
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 14.8% year on year to $745.1 million. The company expects the full year’s revenue to be around $3.15 billion, close to analysts’ estimates. Its non-GAAP profit of $1.13 per share was 18.6% above analysts’ consensus estimates.
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) is an undervalued biotech stock with strong profitability, solid financial health, and reasonable growth prospects, making it a candidate for value investors.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 13.3%. This drawdown was worse than the S&P 500’s 5.8% fall.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Sarepta Therapeutics (NASDAQ:SRPT).
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 14.8% year on year to $745.1 million. The company expects the full year’s revenue to be around $3.15 billion, close to analysts’ estimates. Its non-GAAP profit of $1.13 per share was 18.6% above analysts’ consensus estimates.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
BIOMARIN PHARMACEUTICAL INC has caught the attention as a great value stock. NASDAQ:BMRN excels in profitability, solvency, and liquidity, all while being very reasonably priced.
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating anti-competitive practices.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie (NYSE:ABBV).
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR).
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).
BioMarin's Phase 3 trial shows Palynziq significantly reduces blood Phe in adolescents with PKU. The company plans a regulatory submission for label expansion.
